APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Venous Insufficiency

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Chronic Venous Insufficiency Market Analysis and Forecast 2026-2032

25 December 2025200 pages

Choose your research edition.

Industry ResearchChronic Venous Insufficiency Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Venous Insufficiency Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Chronic Venous Insufficiency Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Venous Insufficiency Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Venous Insufficiency Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Chronic Venous Insufficiency market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Chronic Venous Insufficiency is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Chronic Venous Insufficiency is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Chronic Venous Insufficiency is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Chronic Venous Insufficiency is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Chronic Venous Insufficiency include Suzhou Yinluo Medical Devices, Suzhou Tianhong Shengjie Medical Devices, Shanghai Lanmai Medical Technology, Shanghai Ensheng Medical Technology, Hangzhou Weiqiang Medical Technology, Zylox-Tonbridge Medical Technology, Teva, Sun Pharma and Philips, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Chronic Venous Insufficiency, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chronic Venous Insufficiency, also provides the revenue of main regions and countries. Of the upcoming market potential for Chronic Venous Insufficiency, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chronic Venous Insufficiency revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chronic Venous Insufficiency market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Chronic Venous Insufficiency revenue, projected growth trends, production technology, application and end-user industry.

Chronic Venous Insufficiency Segment by Company

Suzhou Yinluo Medical Devices

Suzhou Tianhong Shengjie Medical Devices

Shanghai Lanmai Medical Technology

Shanghai Ensheng Medical Technology

Hangzhou Weiqiang Medical Technology

Zylox-Tonbridge Medical Technology

Teva

Sun Pharma

Philips

Pfizer

optimed Medizinische Instrumente

Mylan

Medtronic

Cook Ireland

Boston Scientific

BD(Angiomed)

Allergan

AbbVie

Abbott

3M

Chronic Venous Insufficiency Segment by Type

Medical Equipment and Consumables

Drugs

Chronic Venous Insufficiency Segment by Application

Hospital

Clinic

Other

Chronic Venous Insufficiency Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Venous Insufficiency market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Venous Insufficiency and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Venous Insufficiency.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Chronic Venous Insufficiency in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Chronic Venous Insufficiency company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Venous Insufficiency revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chronic Venous Insufficiency Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Medical Equipment and Consumables Major Player Table 3. Drugs Major Player Table 4. Global Chronic Venous Insufficiency Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Chronic Venous Insufficiency Industry Trends Table 9. Chronic Venous Insufficiency Industry Drivers Table 10. Chronic Venous Insufficiency Industry Opportunities and Challenges Table 11. Chronic Venous Insufficiency Industry Restraints Table 12. Global Chronic Venous Insufficiency Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Chronic Venous Insufficiency Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Chronic Venous Insufficiency Market Share by Region (2021-2026) Table 15. Global Chronic Venous Insufficiency Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Chronic Venous Insufficiency Market Share by Region (2027-2032) Table 17. Global Chronic Venous Insufficiency Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Chronic Venous Insufficiency Revenue Market Share by Players (2021-2026) Table 19. Global Chronic Venous Insufficiency Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Chronic Venous Insufficiency Key Players Headquarters & Area Served Table 21. Global Chronic Venous Insufficiency Players, Product Type & Application Table 22. Global Chronic Venous Insufficiency Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Chronic Venous Insufficiency by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Chronic Venous Insufficiency Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Chronic Venous Insufficiency Revenue Market Share by Type (2021-2026) Table 29. Global Chronic Venous Insufficiency Revenue Market Share by Type (2027-2032) Table 30. Global Chronic Venous Insufficiency Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Chronic Venous Insufficiency Revenue Market Share by Application (2021-2026) Table 34. Global Chronic Venous Insufficiency Revenue Market Share by Application (2027-2032) Table 35. Suzhou Yinluo Medical Devices Company Information Table 36. Suzhou Yinluo Medical Devices Business Overview Table 37. Suzhou Yinluo Medical Devices Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Suzhou Yinluo Medical Devices Chronic Venous Insufficiency Product Portfolio Table 39. Suzhou Yinluo Medical Devices Recent Development Table 40. Suzhou Tianhong Shengjie Medical Devices Company Information Table 41. Suzhou Tianhong Shengjie Medical Devices Business Overview Table 42. Suzhou Tianhong Shengjie Medical Devices Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Suzhou Tianhong Shengjie Medical Devices Chronic Venous Insufficiency Product Portfolio Table 44. Suzhou Tianhong Shengjie Medical Devices Recent Development Table 45. Shanghai Lanmai Medical Technology Company Information Table 46. Shanghai Lanmai Medical Technology Business Overview Table 47. Shanghai Lanmai Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Shanghai Lanmai Medical Technology Chronic Venous Insufficiency Product Portfolio Table 49. Shanghai Lanmai Medical Technology Recent Development Table 50. Shanghai Ensheng Medical Technology Company Information Table 51. Shanghai Ensheng Medical Technology Business Overview Table 52. Shanghai Ensheng Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Shanghai Ensheng Medical Technology Chronic Venous Insufficiency Product Portfolio Table 54. Shanghai Ensheng Medical Technology Recent Development Table 55. Hangzhou Weiqiang Medical Technology Company Information Table 56. Hangzhou Weiqiang Medical Technology Business Overview Table 57. Hangzhou Weiqiang Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Hangzhou Weiqiang Medical Technology Chronic Venous Insufficiency Product Portfolio Table 59. Hangzhou Weiqiang Medical Technology Recent Development Table 60. Zylox-Tonbridge Medical Technology Company Information Table 61. Zylox-Tonbridge Medical Technology Business Overview Table 62. Zylox-Tonbridge Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Zylox-Tonbridge Medical Technology Chronic Venous Insufficiency Product Portfolio Table 64. Zylox-Tonbridge Medical Technology Recent Development Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Teva Chronic Venous Insufficiency Product Portfolio Table 69. Teva Recent Development Table 70. Sun Pharma Company Information Table 71. Sun Pharma Business Overview Table 72. Sun Pharma Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sun Pharma Chronic Venous Insufficiency Product Portfolio Table 74. Sun Pharma Recent Development Table 75. Philips Company Information Table 76. Philips Business Overview Table 77. Philips Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Philips Chronic Venous Insufficiency Product Portfolio Table 79. Philips Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Chronic Venous Insufficiency Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Pfizer Chronic Venous Insufficiency Product Portfolio Table 84. Pfizer Recent Development Table 85. optimed Medizinische Instrumente Company Information Table 86. optimed Medizinische Instrumente Business Overview Table 87. optimed Medizinische Instrumente Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. optimed Medizinische Instrumente Chronic Venous Insufficiency Product Portfolio Table 89. optimed Medizinische Instrumente Recent Development Table 90. Mylan Company Information Table 91. Mylan Business Overview Table 92. Mylan Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Mylan Chronic Venous Insufficiency Product Portfolio Table 94. Mylan Recent Development Table 95. Medtronic Company Information Table 96. Medtronic Business Overview Table 97. Medtronic Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Medtronic Chronic Venous Insufficiency Product Portfolio Table 99. Medtronic Recent Development Table 100. Cook Ireland Company Information Table 101. Cook Ireland Business Overview Table 102. Cook Ireland Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Cook Ireland Chronic Venous Insufficiency Product Portfolio Table 104. Cook Ireland Recent Development Table 105. Boston Scientific Company Information Table 106. Boston Scientific Business Overview Table 107. Boston Scientific Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Boston Scientific Chronic Venous Insufficiency Product Portfolio Table 109. Boston Scientific Recent Development Table 110. BD(Angiomed) Company Information Table 111. BD(Angiomed) Business Overview Table 112. BD(Angiomed) Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. BD(Angiomed) Chronic Venous Insufficiency Product Portfolio Table 114. BD(Angiomed) Recent Development Table 115. Allergan Company Information Table 116. Allergan Business Overview Table 117. Allergan Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Allergan Chronic Venous Insufficiency Product Portfolio Table 119. Allergan Recent Development Table 120. AbbVie Company Information Table 121. AbbVie Business Overview Table 122. AbbVie Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. AbbVie Chronic Venous Insufficiency Product Portfolio Table 124. AbbVie Recent Development Table 125. Abbott Company Information Table 126. Abbott Business Overview Table 127. Abbott Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Abbott Chronic Venous Insufficiency Product Portfolio Table 129. Abbott Recent Development Table 130. 3M Company Information Table 131. 3M Business Overview Table 132. 3M Chronic Venous Insufficiency Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. 3M Chronic Venous Insufficiency Product Portfolio Table 134. 3M Recent Development Table 135. North America Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 136. North America Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 137. North America Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Chronic Venous Insufficiency Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Chronic Venous Insufficiency Revenue by Country (US$ Million) & (2027-2032) Table 142. Europe Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 145. Europe Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 146. Europe Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Chronic Venous Insufficiency Revenue by Country (2021-2026) & (US$ Million) Table 148. Europe Chronic Venous Insufficiency Revenue by Country (US$ Million) & (2027-2032) Table 149. China Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 150. China Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 151. China Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 152. China Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Chronic Venous Insufficiency Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Chronic Venous Insufficiency Revenue by Region (US$ Million) & (2021-2026) Table 159. Asia Chronic Venous Insufficiency Revenue by Region (US$ Million) & (2027-2032) Table 160. SAMEA Chronic Venous Insufficiency Revenue by Type (2021-2026) & (US$ Million) Table 161. SAMEA Chronic Venous Insufficiency Revenue by Type (2027-2032) & (US$ Million) Table 162. SAMEA Chronic Venous Insufficiency Revenue by Application (2021-2026) & (US$ Million) Table 163. SAMEA Chronic Venous Insufficiency Revenue by Application (2027-2032) & (US$ Million) Table 164. SAMEA Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. SAMEA Chronic Venous Insufficiency Revenue by Country (2021-2026) & (US$ Million) Table 166. SAMEA Chronic Venous Insufficiency Revenue by Country (US$ Million) & (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Chronic Venous Insufficiency Image Figure 2. Global Chronic Venous Insufficiency Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Venous Insufficiency Market Size Share 2021 VS 2025 VS 2032 Figure 4. Medical Equipment and Consumables Image Figure 5. Drugs Image Figure 6. Global Chronic Venous Insufficiency Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Chronic Venous Insufficiency Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Chronic Venous Insufficiency Market Size (US$ Million) & (2021-2032) Figure 12. Global Chronic Venous Insufficiency Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Chronic Venous Insufficiency Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Chronic Venous Insufficiency Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Chronic Venous Insufficiency Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Chronic Venous Insufficiency Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Venous Insufficiency Revenue Market Share by Type (2021-2032) Figure 19. Global Chronic Venous Insufficiency Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Chronic Venous Insufficiency Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Chronic Venous Insufficiency Revenue Market Share by Application (2021-2032) Figure 22. North America Chronic Venous Insufficiency Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Chronic Venous Insufficiency Revenue Share by Type (2021-2032) Figure 24. North America Chronic Venous Insufficiency Revenue Share by Application (2021-2032) Figure 25. North America Chronic Venous Insufficiency Revenue Share by Country (2021-2032) Figure 26. United States Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Chronic Venous Insufficiency Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Chronic Venous Insufficiency Revenue Share by Type (2021-2032) Figure 31. Europe Chronic Venous Insufficiency Revenue Share by Application (2021-2032) Figure 32. Europe Chronic Venous Insufficiency Revenue Share by Country (2021-2032) Figure 33. Germany Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Chronic Venous Insufficiency Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Chronic Venous Insufficiency Revenue Share by Type (2021-2032) Figure 43. China Chronic Venous Insufficiency Revenue Share by Application (2021-2032) Figure 44. Asia Chronic Venous Insufficiency Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Chronic Venous Insufficiency Revenue Share by Type (2021-2032) Figure 46. Asia Chronic Venous Insufficiency Revenue Share by Application (2021-2032) Figure 47. Asia Chronic Venous Insufficiency Revenue Share by Region (2021-2032) Figure 48. Japan Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Chronic Venous Insufficiency Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Chronic Venous Insufficiency Revenue Share by Type (2021-2032) Figure 56. SAMEA Chronic Venous Insufficiency Revenue Share by Application (2021-2032) Figure 57. SAMEA Chronic Venous Insufficiency Revenue Share by Country (2021-2032) Figure 58. Brazil Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Chronic Venous Insufficiency Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Medical Equipment and Consumables
  • Drugs
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Suzhou Yinluo Medical Devices
  • Suzhou Tianhong Shengjie Medical Devices
  • Shanghai Lanmai Medical Technology
  • Shanghai Ensheng Medical Technology
  • Hangzhou Weiqiang Medical Technology
  • Zylox-Tonbridge Medical Technology
  • Teva
  • Sun Pharma
  • Philips
  • Pfizer
  • optimed Medizinische Instrumente
  • Mylan
  • Medtronic
  • Cook Ireland
  • Boston Scientific
  • BD(Angiomed)
  • Allergan
  • AbbVie
  • Abbott
  • 3M

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chronic Venous Insufficiency Market by Type
  3. 1.2.1 Global Chronic Venous Insufficiency Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Medical Equipment and Consumables
  5. 1.2.3 Drugs
  6. 1.3 Chronic Venous Insufficiency Market by Application
  7. 1.3.1 Global Chronic Venous Insufficiency Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Chronic Venous Insufficiency Market Dynamics
  1. 2.1 Chronic Venous Insufficiency Industry Trends
  2. 2.2 Chronic Venous Insufficiency Industry Drivers
  3. 2.3 Chronic Venous Insufficiency Industry Opportunities and Challenges
  4. 2.4 Chronic Venous Insufficiency Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Chronic Venous Insufficiency Market Perspective (2021-2032)
  2. 3.2 Global Chronic Venous Insufficiency Growth Trends by Region
  3. 3.2.1 Global Chronic Venous Insufficiency Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chronic Venous Insufficiency Market Size by Region (2021-2026)
  5. 3.2.3 Global Chronic Venous Insufficiency Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Chronic Venous Insufficiency Revenue by Players
  2. 4.1.1 Global Chronic Venous Insufficiency Revenue by Players (2021-2026)
  3. 4.1.2 Global Chronic Venous Insufficiency Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Chronic Venous Insufficiency Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chronic Venous Insufficiency Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Chronic Venous Insufficiency Key Players Headquarters & Area Served
  7. 4.4 Global Chronic Venous Insufficiency Players, Product Type & Application
  8. 4.5 Global Chronic Venous Insufficiency Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Chronic Venous Insufficiency Market CR5 and HHI
  11. 4.6.3 2025 Chronic Venous Insufficiency Tier 1, Tier 2, and Tier 3
5 Chronic Venous Insufficiency Market Size by Type
  1. 5.1 Global Chronic Venous Insufficiency Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 5.3 Global Chronic Venous Insufficiency Revenue Market Share by Type (2021-2032)
6 Chronic Venous Insufficiency Market Size by Application
  1. 6.1 Global Chronic Venous Insufficiency Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Chronic Venous Insufficiency Revenue by Application (2021-2032)
  3. 6.3 Global Chronic Venous Insufficiency Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Suzhou Yinluo Medical Devices
  2. 7.1.1 Suzhou Yinluo Medical Devices Company Information
  3. 7.1.2 Suzhou Yinluo Medical Devices Business Overview
  4. 7.1.3 Suzhou Yinluo Medical Devices Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Suzhou Yinluo Medical Devices Chronic Venous Insufficiency Product Portfolio
  6. 7.1.5 Suzhou Yinluo Medical Devices Recent Developments
  7. 7.2 Suzhou Tianhong Shengjie Medical Devices
  8. 7.2.1 Suzhou Tianhong Shengjie Medical Devices Company Information
  9. 7.2.2 Suzhou Tianhong Shengjie Medical Devices Business Overview
  10. 7.2.3 Suzhou Tianhong Shengjie Medical Devices Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Suzhou Tianhong Shengjie Medical Devices Chronic Venous Insufficiency Product Portfolio
  12. 7.2.5 Suzhou Tianhong Shengjie Medical Devices Recent Developments
  13. 7.3 Shanghai Lanmai Medical Technology
  14. 7.3.1 Shanghai Lanmai Medical Technology Company Information
  15. 7.3.2 Shanghai Lanmai Medical Technology Business Overview
  16. 7.3.3 Shanghai Lanmai Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Lanmai Medical Technology Chronic Venous Insufficiency Product Portfolio
  18. 7.3.5 Shanghai Lanmai Medical Technology Recent Developments
  19. 7.4 Shanghai Ensheng Medical Technology
  20. 7.4.1 Shanghai Ensheng Medical Technology Company Information
  21. 7.4.2 Shanghai Ensheng Medical Technology Business Overview
  22. 7.4.3 Shanghai Ensheng Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Shanghai Ensheng Medical Technology Chronic Venous Insufficiency Product Portfolio
  24. 7.4.5 Shanghai Ensheng Medical Technology Recent Developments
  25. 7.5 Hangzhou Weiqiang Medical Technology
  26. 7.5.1 Hangzhou Weiqiang Medical Technology Company Information
  27. 7.5.2 Hangzhou Weiqiang Medical Technology Business Overview
  28. 7.5.3 Hangzhou Weiqiang Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hangzhou Weiqiang Medical Technology Chronic Venous Insufficiency Product Portfolio
  30. 7.5.5 Hangzhou Weiqiang Medical Technology Recent Developments
  31. 7.6 Zylox-Tonbridge Medical Technology
  32. 7.6.1 Zylox-Tonbridge Medical Technology Company Information
  33. 7.6.2 Zylox-Tonbridge Medical Technology Business Overview
  34. 7.6.3 Zylox-Tonbridge Medical Technology Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Zylox-Tonbridge Medical Technology Chronic Venous Insufficiency Product Portfolio
  36. 7.6.5 Zylox-Tonbridge Medical Technology Recent Developments
  37. 7.7 Teva
  38. 7.7.1 Teva Company Information
  39. 7.7.2 Teva Business Overview
  40. 7.7.3 Teva Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Teva Chronic Venous Insufficiency Product Portfolio
  42. 7.7.5 Teva Recent Developments
  43. 7.8 Sun Pharma
  44. 7.8.1 Sun Pharma Company Information
  45. 7.8.2 Sun Pharma Business Overview
  46. 7.8.3 Sun Pharma Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sun Pharma Chronic Venous Insufficiency Product Portfolio
  48. 7.8.5 Sun Pharma Recent Developments
  49. 7.9 Philips
  50. 7.9.1 Philips Company Information
  51. 7.9.2 Philips Business Overview
  52. 7.9.3 Philips Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Philips Chronic Venous Insufficiency Product Portfolio
  54. 7.9.5 Philips Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Chronic Venous Insufficiency Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 optimed Medizinische Instrumente
  62. 7.11.1 optimed Medizinische Instrumente Company Information
  63. 7.11.2 optimed Medizinische Instrumente Business Overview
  64. 7.11.3 optimed Medizinische Instrumente Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  65. 7.11.4 optimed Medizinische Instrumente Chronic Venous Insufficiency Product Portfolio
  66. 7.11.5 optimed Medizinische Instrumente Recent Developments
  67. 7.12 Mylan
  68. 7.12.1 Mylan Company Information
  69. 7.12.2 Mylan Business Overview
  70. 7.12.3 Mylan Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Mylan Chronic Venous Insufficiency Product Portfolio
  72. 7.12.5 Mylan Recent Developments
  73. 7.13 Medtronic
  74. 7.13.1 Medtronic Company Information
  75. 7.13.2 Medtronic Business Overview
  76. 7.13.3 Medtronic Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Medtronic Chronic Venous Insufficiency Product Portfolio
  78. 7.13.5 Medtronic Recent Developments
  79. 7.14 Cook Ireland
  80. 7.14.1 Cook Ireland Company Information
  81. 7.14.2 Cook Ireland Business Overview
  82. 7.14.3 Cook Ireland Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Cook Ireland Chronic Venous Insufficiency Product Portfolio
  84. 7.14.5 Cook Ireland Recent Developments
  85. 7.15 Boston Scientific
  86. 7.15.1 Boston Scientific Company Information
  87. 7.15.2 Boston Scientific Business Overview
  88. 7.15.3 Boston Scientific Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Boston Scientific Chronic Venous Insufficiency Product Portfolio
  90. 7.15.5 Boston Scientific Recent Developments
  91. 7.16 BD(Angiomed)
  92. 7.16.1 BD(Angiomed) Company Information
  93. 7.16.2 BD(Angiomed) Business Overview
  94. 7.16.3 BD(Angiomed) Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BD(Angiomed) Chronic Venous Insufficiency Product Portfolio
  96. 7.16.5 BD(Angiomed) Recent Developments
  97. 7.17 Allergan
  98. 7.17.1 Allergan Company Information
  99. 7.17.2 Allergan Business Overview
  100. 7.17.3 Allergan Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Allergan Chronic Venous Insufficiency Product Portfolio
  102. 7.17.5 Allergan Recent Developments
  103. 7.18 AbbVie
  104. 7.18.1 AbbVie Company Information
  105. 7.18.2 AbbVie Business Overview
  106. 7.18.3 AbbVie Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  107. 7.18.4 AbbVie Chronic Venous Insufficiency Product Portfolio
  108. 7.18.5 AbbVie Recent Developments
  109. 7.19 Abbott
  110. 7.19.1 Abbott Company Information
  111. 7.19.2 Abbott Business Overview
  112. 7.19.3 Abbott Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Abbott Chronic Venous Insufficiency Product Portfolio
  114. 7.19.5 Abbott Recent Developments
  115. 7.20 3M
  116. 7.20.1 3M Company Information
  117. 7.20.2 3M Business Overview
  118. 7.20.3 3M Chronic Venous Insufficiency Revenue and Gross Margin (2021-2026)
  119. 7.20.4 3M Chronic Venous Insufficiency Product Portfolio
  120. 7.20.5 3M Recent Developments
8 North America
  1. 8.1 North America Chronic Venous Insufficiency Revenue (2021-2032)
  2. 8.2 North America Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 8.2.1 North America Chronic Venous Insufficiency Revenue by Type (2021-2026)
  4. 8.2.2 North America Chronic Venous Insufficiency Revenue by Type (2027-2032)
  5. 8.3 North America Chronic Venous Insufficiency Revenue Share by Type (2021-2032)
  6. 8.4 North America Chronic Venous Insufficiency Revenue by Application (2021-2032)
  7. 8.4.1 North America Chronic Venous Insufficiency Revenue by Application (2021-2026)
  8. 8.4.2 North America Chronic Venous Insufficiency Revenue by Application (2027-2032)
  9. 8.5 North America Chronic Venous Insufficiency Revenue Share by Application (2021-2032)
  10. 8.6 North America Chronic Venous Insufficiency Revenue by Country
  11. 8.6.1 North America Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Chronic Venous Insufficiency Revenue by Country (2021-2026)
  13. 8.6.3 North America Chronic Venous Insufficiency Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Chronic Venous Insufficiency Revenue (2021-2032)
  2. 9.2 Europe Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 9.2.1 Europe Chronic Venous Insufficiency Revenue by Type (2021-2026)
  4. 9.2.2 Europe Chronic Venous Insufficiency Revenue by Type (2027-2032)
  5. 9.3 Europe Chronic Venous Insufficiency Revenue Share by Type (2021-2032)
  6. 9.4 Europe Chronic Venous Insufficiency Revenue by Application (2021-2032)
  7. 9.4.1 Europe Chronic Venous Insufficiency Revenue by Application (2021-2026)
  8. 9.4.2 Europe Chronic Venous Insufficiency Revenue by Application (2027-2032)
  9. 9.5 Europe Chronic Venous Insufficiency Revenue Share by Application (2021-2032)
  10. 9.6 Europe Chronic Venous Insufficiency Revenue by Country
  11. 9.6.1 Europe Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Chronic Venous Insufficiency Revenue by Country (2021-2026)
  13. 9.6.3 Europe Chronic Venous Insufficiency Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Chronic Venous Insufficiency Revenue (2021-2032)
  2. 10.2 China Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 10.2.1 China Chronic Venous Insufficiency Revenue by Type (2021-2026)
  4. 10.2.2 China Chronic Venous Insufficiency Revenue by Type (2027-2032)
  5. 10.3 China Chronic Venous Insufficiency Revenue Share by Type (2021-2032)
  6. 10.4 China Chronic Venous Insufficiency Revenue by Application (2021-2032)
  7. 10.4.1 China Chronic Venous Insufficiency Revenue by Application (2021-2026)
  8. 10.4.2 China Chronic Venous Insufficiency Revenue by Application (2027-2032)
  9. 10.5 China Chronic Venous Insufficiency Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chronic Venous Insufficiency Revenue (2021-2032)
  2. 11.2 Asia Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 11.2.1 Asia Chronic Venous Insufficiency Revenue by Type (2021-2026)
  4. 11.2.2 Asia Chronic Venous Insufficiency Revenue by Type (2027-2032)
  5. 11.3 Asia Chronic Venous Insufficiency Revenue Share by Type (2021-2032)
  6. 11.4 Asia Chronic Venous Insufficiency Revenue by Application (2021-2032)
  7. 11.4.1 Asia Chronic Venous Insufficiency Revenue by Application (2021-2026)
  8. 11.4.2 Asia Chronic Venous Insufficiency Revenue by Application (2027-2032)
  9. 11.5 Asia Chronic Venous Insufficiency Revenue Share by Application (2021-2032)
  10. 11.6 Asia Chronic Venous Insufficiency Revenue by Country
  11. 11.6.1 Asia Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Chronic Venous Insufficiency Revenue by Country (2021-2026)
  13. 11.6.3 Asia Chronic Venous Insufficiency Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chronic Venous Insufficiency Revenue (2021-2032)
  2. 12.2 SAMEA Chronic Venous Insufficiency Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Chronic Venous Insufficiency Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Chronic Venous Insufficiency Revenue by Type (2027-2032)
  5. 12.3 SAMEA Chronic Venous Insufficiency Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Chronic Venous Insufficiency Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Chronic Venous Insufficiency Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Chronic Venous Insufficiency Revenue by Application (2027-2032)
  9. 12.5 SAMEA Chronic Venous Insufficiency Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Chronic Venous Insufficiency Revenue by Country
  11. 12.6.1 SAMEA Chronic Venous Insufficiency Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Chronic Venous Insufficiency Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Chronic Venous Insufficiency Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst